Creelan, B. C., Gray, J. E., Tanvetyanon, T., Chiappori, A. A., Yoshida, T., Schell, M. J., . . . Haura, E. B. (2019). Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance. Br J Cancer.

Creelan, Ben C., Jhanelle E. Gray, Tawee Tanvetyanon, Alberto A. Chiappori, Takeshi Yoshida, Michael J. Schell, Scott J. Antonia, und Eric B. Haura. "Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance." Br J Cancer 2019.

Creelan, Ben C., et al. "Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance." Br J Cancer 2019.